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Lysophosphatidylcholine 
acyltransferase 2 (LPCAT2) co-
localises with TLR4 and regulates 
macrophage inflammatory gene 
expression in response to LpS
W. Abate1,3, H. Alrammah1, M. Kiernan1, A. J. tonks2 & S. K. Jackson1 ✉
Despite extensive investigations, an effective treatment for sepsis remains elusive and a better 
understanding of the inflammatory response to infection is required to identify potential new targets 
for therapy. In this study we have used RNAi technology to show, for the first time, that the inducible 
lysophosphatidylcholine acyltransferase 2 (LPCAT2) plays a key role in macrophage inflammatory 
gene expression in response to stimulation with bacterial ligands. Using siRNA- or shRNA-mediated 
knockdown, we demonstrate that, in contrast to the constitutive LPCAT1, LPCAT2 is required for 
macrophage cytokine gene expression and release in response to TLR4 and TLR2 ligand stimulation 
but not for TLR-independent stimuli. In addition, cells transfected to overexpress LPCAT2 exhibited 
increased expression of inflammatory genes in response to LPS and other bacterial ligands. 
Furthermore, we have used immunoprecipitation and Western blotting to show that in response to 
LPS, LPCAT2, but not LPCAT1, rapidly associates with TLR4 and translocates to membrane lipid raft 
domains. Our data thus suggest a novel mechanism for the regulation of inflammatory gene expression 
in response to bacterial stimuli and highlight LPCAT2 as a potential therapeutic target for development 
of anti-inflammatory and anti-sepsis therapies.
Sepsis is a life-threatening condition that is estimated to result in as many as 20,000 deaths per day Worldwide1. 
Despite extensive investigations and numerous clinical trials, there is currently no effective therapy for sepsis2. 
Thus, identification of new therapeutic options for patients suffering from sepsis is paramount. Bacterial mole-
cules such as lipopolysaccharide (LPS) play key roles in the development of sepsis. Detection of LPS by innate 
immune cells is vital for host defense against Gram-negative bacteria yet unregulated responses can produce 
excessive cytokine release, which can ultimately lead to the cardiovascular derangements and organ dysfunction 
that are the hallmarks of severe sepsis3–5. LPS activates the TLR4/MD2 complex on cells such as macrophages 
leading to intracellular signalling and activation of NF-κB and MAPKs which culminates in the release of inflam-
matory cytokines6 and lipid mediators7. The approach of blocking individual inflammatory mediators has not 
proved successful in clinical sepsis trials1,8 and therefore a better understanding of the inflammatory pathways 
activated by TLRs is required to develop effective therapies.
In addition to being the major and fundamental structural components of biological membranes, phospholip-
ids (PLs) and their metabolites play critical roles in cell signaling and activation9. PL metabolites, such as lysoPLs 
(LPL) and oxidised PL (oxPL), have been shown to mediate inflammatory responses and to influence outcome in 
experimental models of sepsis10. Diverse phospholipid composition profiles are required for membrane fluidity, 
vesicle trafficking, and special domain formation for signalling11,12. The mechanistic details of the remodelling 
process that underlie different phospholipid compositions have recently become better understood. Membrane 
diversity and asymmetry is maintained by the concerted deacylation and reacylation of phospholipids in the 
so-called ‘Land’s Cycle’13. Deacylation reactions are mediated by phospholipases, in particular phospholipase A2 
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(PLA2), the activity of which is increased in inflammation. The reacylation of the major membrane phospho-
lipid, phosphatidylcholine (PC), is performed by a family of LysoPC acyltransferase (LPCAT) enzymes. Recent 
studies have revealed four enzymes with LPCAT activity, namely LPCAT1, LPCAT2, LPCAT3 and LPCAT414. 
In addition to LPCAT activity, LPCAT1 and LPCAT2 have been shown to express lyso-platelet activating factor 
acetyltransferase (LPAFAT) activity15,16. LPCAT1 has been found to be highly expressed in lung tissue where it 
regulates surfactant lipid generation15,17,18. LPCAT2 has been reported to be expressed in inflammatory cells and 
to be up-regulated by LPS stimulation15.
Acyltransferase activity has been linked to inflammatory disease. For example the ratio of PC/LysoPC in 
plasma has been shown to be a measure of inflammation in rheumatoid arthritis19, and lysoPC, a major compo-
nent of oxidized low density lipoprotein, has been shown to be beneficial in experimental sepsis models20. Plasma 
LysoPC levels are decreased in sepsis patients and decreased LysoPC/PC ratios are highly correlated with sepsis 
mortality10.
Our group has been investigating the role of phospholipid metabolites in the inflammatory responses to LPS. 
Our previous studies, using global pharmacological inhibition of LPCAT, suggested a key role for these enzymes 
in inflammation although the specific isoform of LPCAT responsible for these effects was not elucidated11,21,22. 
LPCAT1 and LPCAT2 have been shown to be differentially expressed and have distinct phospholipid metabolis-
ing functions [15,16], and therefore the identity of the LPCAT isoform regulating inflammation will be key to the 
development of targeted anti-inflammatory therapies. In the current study, we exploited the recent availability 
of antibodies and sequence data for LPCAT1 and 215,17,18 to develop RNA interference (RNAi) technology to 
determine the role played by LPCAT1 and 2 in bacterial-induced inflammatory responses. We here show that LPS 
stimulates association between LPCAT2 and TLR4 and the translocation of LPCAT2 into membrane lipid raft 
domains. We also show that cells overexpressing LPCAT2 produce enhanced inflammatory gene expression in 
response to LPS and other bacterial ligands and that selective knockdown of LPCAT2 inhibits the inflammatory 
gene expression. Thus, our data support a major role for LPCAT2 in the regulation of inflammatory responses to 
LPS and other bacterial TLR ligands.
Results
LPCAT2 is expressed in resting macrophages and is induced by TLR4 and TLR2 ligands. The 
presence and the absolute transcript level of LPCAT mRNA was determined using a real time quantitative PCR. 
RAW264.7 cells expressed both LPCAT1 and -2 in a resting state. The amount of LPCAT1 transcript was eight 
fold higher than LPCAT2 (5.575 + 0.15 Vs. 4.671 + 0.14, Log10 Mean transcript level + SE, p = 0.0115) in unstim-
ulated cells (Fig. 1A). It has been shown that incubation of macrophages with TLR4 or -9 ligands for 16 hours 
up-regulates the mRNA expression of LPCAT215. In the present work, we further examined the induction of both 
LPCAT1 and 2 by the TLR4 ligand LPS and the TLR2 ligand lipoteichoic acid (LTA). We found that the level of 
LPCAT2 expression was significantly up-regulated when the cells were stimulated with either TLR2 or TLR4 
ligands after 6 hours. In contrast, LPCAT1 mRNA expression was not significantly altered when the cells were 
stimulated with LPS or LTA up to 24 hours compared to resting cells (Fig. 1B,C).
LPCAT2 translocates to membrane lipid raft domains upon cell stimulation with LPS. To assess 
the localisation of LPCAT1 and 2 inside the cells, the cytosolic, nuclear and membrane fractions of resting cells and 
cells stimulated with LPS were isolated by successive detergent extraction24. The distribution profile of LPCAT1 and 
-2 inside the cells was identical and both enzymes were present in the membrane and nuclear factions but not in the 
cytosol (Fig. 2A). In resting cells, the majority of the LPCAT1 and LPCAT2 were found in the non-raft domain of the 
membrane (Fig. 2B). However, on stimulation of cells with LPS, LPCAT2 was found to translocate to the lipid raft 
domain in contrast to LPCAT1 which did not increase in the lipid raft fraction (Fig. 2B–D).
Knockdown of LPCAT2 by siRNA down-regulates inflammatory cytokine gene expression. 
The expression of LPCAT1 and 2 were successfully suppressed by small interfering RNA with 81.35 + 6.4% and 
80.09 + 1.36 per cent knockdown respectively with no significant effect of cytotoxicity from the transfection rea-
gent (Fig. 3A). Using this optimal siRNA knockdown of LPCAT1 and -2 expression, the effect of LPCAT1 or -2 
silencing on LPS-induced cytokine gene expression was initially investigated using real time quantitative PCR. 
We here demonstrate, for the first time, that the inhibition of LPCAT2 expression significantly down-regulates 
the mRNA expression of LPS-induced TNF-α, IL-6 and IL-10 (Fig. 3B–D). The effect of LPCAT2 inhibition 
on LPS-induced protein release was also studied using a Milliplex MAP mouse multiplex kit. The release of 
LPS-mediated inflammatory cytokines was also markedly reduced following the siRNA suppression of LPCAT2 
(Fig. 3E,F) which mirrored the reduction in mRNA of the inflammatory cytokines. In contrast to LPCAT2 silenc-
ing, siRNA knockdown of LPCAT1 had no effect on LPS-induced inflammatory cytokine gene expression at 
either mRNA or protein level (Fig. 3B–F).
The modulation of RAW264.7 cell inflammatory responses by LPCAT2 inhibition was not restricted to 
stimulation with TLR4 ligands. RAW264.7 cells respond strongly to stimulation with lipoteichoic acid (LTA) or 
Pam3Cys, which are TLR2/6 and TLR2/1 ligands respectively26. We found that cytokine gene expression was also 
markedly suppressed in cells with siRNA knockdown of LPCAT2 stimulated with either LTA or Pam3Cys (data 
not shown). However, the inhibition of LPCAT1 by siRNA had no effect on either LTA or PAM3Cys-induced 
responses (data not shown).
To confirm these results in ex vivo cells, LPCAT1 and 2 were knocked down by siRNA in peritoneal 
macrophages which were collected and isolated as described by Zhang et al., 200823. The expression level of 
LPS-induced TNFα mRNA and protein release from peritoneal macrophages stimulated with LPS was signifi-
cantly reduced when the expression of the LPCAT2 was suppressed (Fig. 4A–C). However, as with the RAW264.7 
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cells, siRNA knockdown of LPCAT1 had no effect on LPS-induced inflammatory cytokine gene expression in the 
peritoneal macrophages (results not shown).
The effect of LPCAT2 on LPS-induced responses was not unique to murine macrophages. When the expres-
sion of LPCAT2 was silenced in the human monocyte cell line MonoMac6 (MM6) using shRNA, there was also 
a marked down-regulation of pro-inflammatory cytokines when the cells were stimulated with LPS (Fig. 4D,E).
Overexpression of LPCAT2 produces enhanced inflammatory responses. We have shown 
above that selective inhibition of LPCAT2 gene expression inhibits the inflammatory response to the TLR4 and 
TLR2 ligands, LPS and LTA. To further show the role of LPCAT2 in macrophage responses to bacterial ligands, 
RAW264.7 cells were transfected with a plasmid carrying the LPCAT2 gene insert. Macrophages carrying the 
insert showed increased expression of LPCAT2 compared with cells transfected with empty vector (Fig. 5A). 
Figure 1. The level of expression of LPCAT1 and 2 and their induction by LPS or LTA in RAW264.7 cells. 
The copy number for the LPCATs in RAW264.7 cells were determined as described in the methods section. In 
resting cells the level of LPCAT1 transcripts was relatively higher than LPCAT2 (A). LPCAT 1 and LPCAT2 
mRNA expression in RAW264.7 cells stimulated either LPS (1 µg/mL) (B) or LTA (10 µg/mL) showing the 
inducibility of LPCAT2 by these ligands (C). n = 3; *p < 0.05 Vs LPCAT1.
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Expression of LPCAT2 was further enhanced by LPS stimulation (Fig. 5B) confirming the induction of the trans-
fected LPCAT2. Cells overexpressing LPCAT2 showed increased expression of TNF-α gene (Fig. 5C) and protein 
(Fig. 5D) following stimulation with LPS. Moreover, when the cells transfected with LPCAT2 were also subject 
to siRNA knockdown of LPCAT2 (Fig. 5E), the LPS stimulated gene expression of TNF-α was again significantly 
inhibited (Fig. 5F). These results support a key role for LPCAT2 in macrophage inflammatory responses.
LPCAT2 does not mediate cell responses to TLR-independent ligands. To assess the role of 
LPCAT2 on cell responses to TLR-independent ligands, LPCAT2 expression was silenced in RAW264.7 cells 
that were stimulated with the soluble activator phorbol 12-myristate 13-acetate (PMA) and cell activation was 
determined by reactive oxygen species (ROS) generation using flow cytometry. As shown in Fig. 6A, there was 
no difference in ROS production in response to PMA when cells were transfected with control negative siRNA 
or LPCAT2 siRNA. However, ROS generation was significantly impaired in LPCAT2 siRNA transfected cells 
stimulated with LPS. This result indicates that LPCAT2 mediates cell inflammatory responses to TLR ligands but 
not to TLR-independent stimuli.
Figure 2. Sub-cellular location of LPCAT1 and LPCAT2. Different cellular fractions were isolated and each of 
the fractions was probed for LPCAT1 or 2 by immunoblotting. Both LPCAT1 and 2 exist in the nuclear- rich 
fractions (Histone H3 used as a marker) but not in the cytosol (β-tubulin used as cytosolic marker) and their 
relative abundance does not change following LPS stimulation (A). Isolation of membrane fractions showing 
that the majority of LPCAT1 and 2 is expressed in the non-raft membrane domain but the level of LPCAT2 
is increased in lipid raft domains after LPS stimulation while the level of LPCAT1 remains unchanged (B). 
Densitometry analysis of the fractions from B are shown for LPCAT2 in (C) and LPCAT1 in (D).
5Scientific RepoRtS |        (2020) 10:10355  | https://doi.org/10.1038/s41598-020-67000-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
LPCAT2 does not affect CD14, TLR2 or TLR4 Expression. To investigate how LPCAT2 might regulate 
macrophage inflammatory responses to bacterial ligands, the expression of the proximal signalling receptors 
CD14, TLR2 and TLR4 was determined in LPCAT2 siRNA transfected and control cells after stimulation with 
LPS or LTA for 4 hours. Inhibition of LPCAT2 had no effect on the expression of CD14, TLR4 or TLR2 mRNA 
expression after cell stimulation with either LPS or LTA. LPCAT2 silencing also had no effect on the expression of 
cell surface TLR2 or TLR4 (data not shown).
LPCAT2 is required for LPS-induced p38 phosphorylation. The mitogen-activated protein kinases 
(MAPKs) are crucial serine/ threonine signalling kinases which are activated by phosphorylation resulting in reg-
ulation of cellular responses through the modulation of gene expression in the nucleus27. LPS has been shown to 
induce phosphorylation of p38 and activated p38 regulates LPS-induced inflammatory responses28–30. Therefore 
we assessed the impact of LPCAT2 inhibition on p38 phosphorylation following cell stimulation with LPS. As 
Figure 3. Inhibition of LPCAT2 by siRNA significantly down-regulates LPS-induced inflammatory cytokine 
gene expression and protein release. Treatment of RAW264.7 cells with LPCAT1 or LPCAT2 siRNA resulted in 
81.35 + 6.4 and 80.09 + 1.36 per cent knockdown of LPCAT1 and 2 expression, respectively, compared to the 
treatment with a control negative siRNA (A). Following siRNA knockdown of LPCAT1 or LPCAT2, cells were 
stimulated with LPS at 1 µg/mL, for either 4 hours, for cytokine mRNA expression (B–D) or 24 hours for protein 
release (E,F). *p < 0.05 Vs negative siRNA (B–F).
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expected, there was a significant up-regulation of p38 phosphorylation after 30 minutes of LPS treatment in con-
trol cells transfected with negative siRNA. However, the phosphorylation of p38 was markedly reduced in cells 
in which LPCAT2 was silenced before stimulation with LPS (Fig. 6B). This suggests that LPCAT2 is required for 
complete phosphorylation of p38 following cell stimulation with LPS.
LPS stimulation induces association between TLR4 and LPCAT2. The physical association 
of LPCAT2 with TLR4 in resting cells and cells stimulated with LPS was examined to further clarify the role 
of LPCAT2 in LPS-induced responses. The cell lysate was pre-cleared with normal antibodies raised in the 
same species that anti-TLR4 and anti-LPCAT2 antibodies were raised to reduce non-specific binding before 
immune-precipitation (IP) was carried out using anti-TLR4 or anti-LPCAT2 antibodies. In unstimulated cells, 
there was minimal association between TLR4 and LPCAT2. However, following stimulation with LPS for 15 min-
utes, immunoprecipitation of TLR4 revealed LPCAT2 to be associated with it. This association was transient 
Figure 4. LPCAT2 silencing reduces LPS-induced TNF-α gene expression and protein release from mouse 
peritoneal macrophages and a human monocyte cell line. LPCAT2 expression was significantly reduced by 
incubation of primary mouse peritoneal macrophages with LPCAT2 siRNA (p = 0.0192 vs control negative 
siRNA) (A). LPCAT2 silenced primary macrophages show a significant reduction in TNF-α gene expression 
(B) and protein release (C) following stimulation with LPS (100ug/ml). Transduction of the human monocytic 
cell line, MM6, with shRNA lentiviral particles targeting the LPCAT2 gene resulted in reduced production 
of TNF-α (D) and IL-6 (E) cytokines following LPS stimulation. *p < 0.05 vs negative siRNA (B,C) vs vector 
control (D,E).
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and had reduced by 30 minutes (Fig. 6C). Similarly, the association between TLR4 and LPCAT2 was also seen in 
LPS-stimulated cells when LPCAT2 was immune-precipitated and TLR4 was probed (Fig. 6C). When the asso-
ciation between LPCAT1 and TLR4 was explored in a similar fashion, no association of these two proteins was 
found following stimulation of the cells with LPS (data not shown).
Taken together, these results show that following LPS stimulation, inducible LPCAT2 translocates to mem-
brane lipid raft domains and directly interacts with TLR4 to regulate inflammatory responses in macrophages. 
This demonstrates a novel role for a phospholipid metabolising enzyme in macrophage activation and inflamma-
tory responses.
Figure 5. Overexpression of LPCAT2 gene markedly upregulates LPS-induced TNFα gene expression and 
protein release. The RAW264 cells were transfected with plasmid carrying the LPCAT2 insert (labelled as 
LPCAT2), which results in a significant increase in the LPCAT2 gene expression (A). This overexpression is 
further increased when the cells were stimulated with LPS (B). The overexpression of LPCAT2 significantly 
increases TNFα gene expression (C) and protein release (D). siRNA silencing significantly reduced LPCAT2 
expression in RAW264 cells carrying the LPCAT2 plasmid (E) and significantly inhibited TNFα gene 
expression in these cells (F). Data represents the mean of four independent experiments (n = 4) ± standard 
error. *p < 0.05, **p < 0.01, **p < 0.001.
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Discussion
Macrophages play a key role in a variety of inflammatory conditions including sepsis, a life-threatening organ 
dysfunction caused by a dysregulated host response to infection which has proved extremely difficult to treat and 
carries a high mortality1,31,32. We previously reported that LPCAT is important for macrophage inflammatory 
responses to LPS and other bacterial stimuli, although the isoform of LPCAT responsible for these effects was 
unknown11,21,22. Using the LPCAT sequence data and RNAi technology, we now show that LPCAT2 plays a key 
role in the inflammatory responses of macrophages to stimulation with bacterial ligands. We demonstrate that 
in contrast to LPCAT1, LPCAT2 is required for cytokine gene expression in response to TLR4 and TLR2 ligand 
stimulation. Furthermore, our results indicate that this activity may be elicited through direct association of 
LPCAT2 with TLR4 in membrane lipid raft domains.
LPS induces LPCAT2 translocation to membrane lipid raft domains and association with 
TLR4. The tissue locations and activities of LPCAT1 and LPCAT2 are the subject of current debate. LPCAT1 
has been found to be highly expressed in lung tissue where it regulates surfactant lipid generation17,18. LPCAT2 
has been reported to be expressed in inflammatory cells and to be up-regulated by LPS stimulation15. However, 
previous studies have not reported on the expression level of these enzymes simultaneously within a cell type. 
Here, we determined the exact copy number of endogenous LPCAT1 and LPCAT2 in RAW264.7 macrophages. 
Surprisingly, under resting conditions, LPCAT1 was more abundantly expressed than LPCAT2 in these cells. 
However, after 6 hours of stimulation with the bacterial ligands LPS or LTA, the expression of LPCAT2 was 
dramatically and significantly increased and remained elevated for over 24 hours of stimulation while the 
level of LPCAT1 remained unchanged. Such induction of LPCAT2 expression has been reported previously in 
thioglycolate-elicited murine macrophages although it required 16 hours of LPS stimulation15. Our immunopre-
cipitation experiments revealed that LPS stimulation caused a rapid and reversible association between LPCAT2 
and TLR4 (Fig. 6C). Such an association was not evident with LPCAT1. This result, together with the inhibition 
Figure 6. LPCAT2 inhibition had no effect on PMA-induced total reactive oxygen species (ROS) generation 
while it suppressed LPS-induced ROS production (A). When RAW264.7 cells were stimulated with LPS 
30 minutes after they had been transfected with LPCAT2 or control siRNA for 24 hours, LPS-induced activation 
of p38 was significantly reduced in cells treated with siRNA to LPCAT2 (B). LPS stimulation also induces 
the physical association between LPCAT2 and TLR4 (C). The physical association of LPCAT2 and TLR4 was 
demonstrated by immuno-precipitation (IP) after the cells were stimulated with LPS for 15 or 30 minutes. 
LPCAT2 and TLR4 were detected by immunoblotting following IP using anti-TLR4 and anti-LPCAT2 
antibodies respectively (C).
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in macrophage responses following knockdown of LPCAT2 expression, strongly suggests that the association 
between LPCAT2 and TLR4 facilitates activation of the TLR4 signalling pathways and gene expression.
We further examined the sub-cellular localisation of LPCAT. Both LPCAT1 and LPCAT2 were expressed in 
the membrane and nuclear fractions but not in the cytosolic fraction of the RAW264.7 cells. Interestingly, LPS 
stimulation of the cells did not increase the amount of LPCAT1 or LPCAT2 in the nuclear fraction. This is in 
contrast to a recent study that reported the cytosolic presence of LPCAT1 in a murine lung epithelial cell line and 
its translocation to the nucleus by LPS stimulation33,34. The difference in cytosolic expression could be due to dif-
ferences in the cell types (lung epithelial versus macrophage) and in the methodology used. In our experiments, 
following separation of the nuclei, the cell lysate was further spun to separate the cytosolic and membrane frac-
tions. However the studies by Zou and co-workers33,34 considered the whole lysate as cytosolic following isolation 
of the nuclei. These authors further showed that LPCAT1 can acylate histone and modulate gene expression33. The 
biological significance of the presence of LPCAT2 in the nuclei of macrophages is currently under investigation 
in our laboratory but it is possible that LPCAT2 may also acylate or acetylate nuclear proteins and regulate gene 
expression in macrophages.
In resting cells, we found LPCAT1 and LPCAT2 to be located mainly in the non-lipid raft fractions of the cell 
membranes. A previous study reported that LPCAT2 exists both in the raft and non-raft domains of an intesti-
nal epithelial cell line35. However, our study shows that following stimulation with LPS, a significant portion of 
the LPCAT2 translocates into the lipid raft domains while LPCAT1 remains only in the non-raft fraction. This 
demonstration that LPCAT2 can translocate to raft domains in activated cells, coupled with our findings of the 
LPS-induced association between LPCAT2 and TLR4, suggest an important step in the mechanism by which this 
enzyme can regulate inflammatory pathways in macrophages.
LPCAT2 mediates the inflammatory response to LPS. This study has shown that LPS induces the 
translocation of LPCAT2 into membrane raft domains and stimulates the association between LPCAT2 and 
TLR4. Thus, we hypothesise that through these mechanisms LPCAT2 participates in the regulation of inflam-
matory responses to LPS. We previously showed, using a pharmacological inhibitor, that LPCAT could regulate 
inflammatory responses to LPS11,21,36. However, the LPCAT isoform responsible for this regulation and potential 
mechanisms were unknown. Here we show, using siRNA knockdown experiments, that LPCAT2 is the isoform 
that mediates inflammatory responses to LPS and other bacterial ligands. The inhibition of inflammatory gene 
expression by LPCAT2 knockdown was significant but not total. This may reflect the incomplete inhibition of 
LPCAT2 mRNA expression by siRNA used (80%) and that other molecules might also regulate these responses. 
However, the major reduction in cytokine gene expression in response to LPS stimulation by LPCAT2 knock-
down suggests that this enzyme plays a significant role in controlling these inflammatory responses. In addition, 
knockdown of LPCAT2 resulted in inhibition of LPS-induced phosphorylation of the critical p38 MAPK sug-
gesting that LPCAT2 acts upstream of p38. In contrast, LPCAT1 was found to have no role in the induction of 
inflammatory responses in macrophages. Moreover, LPCAT2 was found to specifically regulate TLR-mediated 
responses, as ROS production in response to the TLR-independent soluble stimulus PMA was not inhibited in the 
siRNA transfected RAW cells while LPS-induced ROS production was inhibited. The regulation of TLR-mediated 
responses by LPCAT2 was not restricted to the RAW264.7 macrophages. Knockdown of LPCAT2 in murine peri-
toneal macrophages also resulted in significant inhibition of LPS stimulated inflammatory cytokine expression 
and protein release. This suggests that the LPCAT2 mediated regulation of macrophage inflammatory responses 
is not restricted to cell lines but also occurs in cells in vivo. Furthermore, the activity of LPCAT2 in regulating 
inflammatory responses was not restricted to murine cells. Knockdown of LPCAT2 expression using shRNA in 
the human monocyte cell line, MM6, also significantly inhibited the inflammatory cytokine responses to LPS. 
This suggests that LPCAT2 regulation of inflammatory gene expression to bacterial stimulation may be a com-
mon mechanism in innate immune cells. Interestingly, this regulation was not mediated by affecting the transcript 
level or surface expression of the Toll-like receptors or the accessory molecule CD14.
The acyltransferase activity of LPCAT2 plays an important role in the storage of phospholipid precursors 
of PAF and eicosanoids37. LPCAT2 catalyses the membrane biogenesis (LPCAT activity) of inflammatory cells 
while producing PAF (LPAFAT activity) in response to external stimuli15. However, this is the first report of 
LPCAT2 mediating inflammatory protein expression in innate immune cells. Since the level of LPCAT2 in the 
membrane raft fraction increased following LPS stimulation and we found a physical association between TLR4 
and LPCAT2, we hypothesise that LPCAT2 may facilitate the recruitment of signalling proteins or their adaptors 
to lipid raft domains thereby affecting the TLR-induced responses. A recent report has demonstrated that LPS 
induces phosphorylation of LPCAT2 by MAPK-activated protein kinase 2 (MK2) to affect enzyme activity38. We 
do not know if phosphorylation of LPCAT2 is also required to mediate its effect on inflammatory gene expres-
sion. Previously, we showed that pharmacological inhibition of LPCAT activity also inhibited inflammatory 
gene expression in response to LPS11,21,36. This suggests that the acyltransferase activity of LPCAT2 might also 
be required for modulating the cytokine gene expression seen in this study. As LPCAT2 has been shown to have 
both LPCAT and LPAFAT activity15 it remains to be determined which activity may have effects on TLR-induced 
gene expression.
In conclusion, our results show that in response to cell stimulation with LPS, LPCAT2, a member of the 
lysophospholipid acyltransferases, translocates to membrane lipid raft domains, and associates with TLR4 to 
facilitate inflammatory gene expression via activation of p38 MAPK. This study has shown that an enzyme that 
regulates membrane phospholipid metabolism can also regulate innate immune inflammatory protein expression 
in response to bacterial ligands. LPCAT2 may thus be a novel regulator of inflammation in innate immune cells 
and highlights LPCAT2 as a potential novel target in the development of new therapies for conditions with unreg-
ulated inflammatory responses such as sepsis.
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Materials and Methods
Most of the reagents were obtained from Sigma-Aldrich® UK unless otherwise stated. The siRNAs, reverse tran-
scription and Power SYBR Green® kits, OPTI-MEM medium, Geneticin antibiotic, Lipofectamine2000 trans-
fection reagent and pre-cast SDS-PAGE gels were from Life Technologies, UK. INTERFERin was bought from 
PolyPlus (supplied by Source Bioscience, UK). PE-conjugated Anti-TLR-2 and -4 were supplied by eBioscience 
Ltd (UK) while antibodies for phospho p38, histone H3, and β-tubulin were supplied by New England Biolab 
(UK). Anti-LPCAT2 antibodies were bought from Santa Cruz Biotechnology Inc. (supplied by Insight biotech-
nology, UK) and Novus Biologicals (UK) while LPCAT1 antibody is from Proteintech Europe (UK). Anti-TLR4 
and anti-Giα2 antibodies and Protein A/G Plus agarose Bead were from Santa Cruz Biotechnology Inc. (sup-
plied by Insight biotechnology, UK). Anti-GAPDH antibody, PVDF membrane, Milliplex multiple analyte panel 
(MAP) mouse multiplex kit and PAM3Cys were from Merck-Millipore UK Ltd (UK). The True ORF Gold plas-
mids with or without murine LPCAT- 2 insert, anti-FLAG antibody and Alpha-Gold competent bacteria were 
supplied by Origene, USA. All cell culture consumables were from Lonza Ltd (UK) except the foetal bovine serum 
which was obtained from BioSera (supplied by Labtech International Ltd, UK). Total reactive oxygen species 
(ROS) detection kit was supplied by ENZO Life Sciences (UK) while the human IL-6 and TNF-α ELISA DuoSet 
kits were purchased from R&D systems Europe Ltd UK.
Cell lines and culture. The RAW264.7 murine macrophage cell line was from ECCAC (supplied by Culture 
Collection, Public Health England, UK). The human monocyte cell line MonoMac 6 (MM6) was obtained from 
the German collection of microorganisms and cell cultures (DSMZ, Germany). RAW264.7 cells were cultured 
in DMEM Medium supplemented with 10% foetal bovine serum (FBS) and 2 mM glutamine (DMEM complete 
medium) at 37 °C in a 5% CO2-humidified atmosphere. MM6 cells were cultured in RPMI-1640 medium, supple-
mented with 10% FBS, 1% 2 mM L-glutamine, 1% nonessential amino acids and 1% sodium pyruvate at 37 °C in 
a 5% CO2-humidified atmosphere.
Animals. The peritoneal macrophages were harvested from C57BL/6 mouse strain. The mice were bred locally 
and were used between 6 to 8 weeks old. All experimental protocols were approved by Plymouth University reg-
ulations under UK Home Office license and all methods were carried out in accordance with relevant guidelines 
and regulations. All mice were maintained at the Plymouth University Animal Care Facility. The animals were 
fed a standard chow pellet diet and had free access to water. All animals were maintained on a 12-h light, 12-h 
dark cycle. The resident peritoneal macrophages were collected and isolated as described by Zhang et al., (2008)23 
following CO2 euthanasia.
Expansion and purification of plasmids. The True ORF Gold plasmids which carries a kanamycin 
resistance gene (with and without murine LPCAT2 insert) was expanded using Alpha-Gold competent bacteria 
according the supplier instruction. Briefly; 1 µg/mL of the plasmid are incubated with 10 µL of the bacteria for 
30 minutes on ice followed by incubation at 42 °C for 45 seconds. The transformed bacteria colonies were selected 
by growing the bacteria on a LB-plate containing 25 µg/ml of Kanamycin. The colonies was transferred into an 
LB broth containing kanamycin at a concentration of 60 µg/mL and incubated while shaken for 12 hours. The 
plasmids are purified using GenEluteTM Plasmid Miniprep Kit according the supplier instruction.
Transfection RAW264 cells with plasmid containing the LPCAT2 insert. RAW264.7 cells at a con-
centration of 106 cells/well were seeded on a 6-wells plate (2.5 mL of DMEM medium) and incubated overnight. 
The cells were then transfected with a vector or plasmid containing the LPCAT2 insert (2.5 µg) in the presence 
of 9 µL Lipofectamine2000 TM using OPTI-MEM medium. After 24 hours, the full DMEM medium is changed 
and the cells further incubated for 24 hours. The over-expression was checked by RT-PCR and western blotting.
siRNA and shRNA inhibition of LPCATs. RAW264.7 cells at 2 × 105cells/2.5 mL/well (for RT-PCR) or 7 
× 104 cells/1 mL/ well (for multiplex cytokine protein assay) were seeded onto 6-well or 12-well plates respectively 
in DMEM complete medium and incubated for 24 h. The primary peritoneal macrophages once isolated seeded 
at 0.25 × 106cells/mL onto 25 cm2 flasks (4 mL) in DMEM complete medium containing penicillin/ streptomycin 
and antimycotic agent and incubated for 24 h. The cells were then transfected in serum free OPTI-MEM medium 
with a control negative siRNA (Ambion), or siRNA directed against LPCAT1 (Ambion siRNA ID s102346) or 
LPCAT2 (Ambion siRNA ID s114512) at a final concentration of 5 nM (for RAW264.7) and 10 nM (peritoneal 
macrophages) using INTERFERin transfection reagent. After 24 h, the medium was changed and complete 
DMEM medium added and the cells were stimulated with the bacterial agonists. For the shRNA experiments, the 
lentiviral particles produced from sequence verified lentiviral plasmid vectors pLK0.1-TRC-shRNA -puro, target-
ing the LPCAT2 gene, were purchased from Sigma Aldrich UK (Mission® TRC shRNA TRCN0000055780). As 
a control, shRNA deficient pLK0.1-TRC- puro lentiviral particles were used. MM6 cells were seeded at a density 
of 1.6 ×104 per well of a 96 well plate and transduced with pLK0.1-TRC-shRNA –puro expressing lentivirus or 
pLK0.1-TRC-puro control lentivirus at a multiplicity of infection (MOI) of 50 in the presence of hexadimethrine 
bromide. Cells were cultured for 72 hours, with regular medium changes before puromycin selection (0.5 µg/ml) 
of shRNA expressing cells.
Reverse transcription and real time quantitative PCR (RT-qPCR). Total RNA was extracted using 
guanidinium thiocyanate-phenol-bromochloropropane and the total RNA concentration was determined using 
NanoVue spectrophotometer (GE Healthcare, UK). The purity was assessed by examining the ratio of the absorb-
ance measurement at 260 to 280 nm while the integrity was assessed by running a gel electrophoresis on 1% 
denaturing agarose gel. The reverse transcription was done using High Capacity RNA-to-DNA kit for 0.5 µg total 
RNA according to manufacturer’s instructions. The quantitative real time PCR was performed using Power SYBR 
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Green and StepOnePlus thermal cycler (Applied Biosystems, UK). The primers for LPCAT1, LPCAT2, TNF-α, 
IL-6, IL-10, GAPDH, CD14, TLR2 and TLR4 (Table 1) were designed using Primer Express 3.0 software (Applied 
Biosystems, UK) to amplify 100 bp product for all the targets.
Relative quantitation of LPCAT1 and 2 expressions. The copy numbers of LPCAT1 and 2 were deter-
mined using a relative standard curve of a known concentration of a 100 bp PCR product (GAPDH). A 7-point 
standard was prepared using this PCR product by serial dilutions (1:5) in the range of 0.8 ng/µL to 5.12 ×10−5 ng/
µL. The quantitative real time PCR was performed using primer sets designed to produce 100 bp product for 
LPCAT1 and 2, on cDNA generated from the reverse transcription of the resting (naive) cells to determine the 
expression and the exact copy number of the two LPCATs per cell. The amount of LPCAT1 and 2 in ng/µL was 
calculated using a formula 10 (Ct-b)/m, where Ct is the threshold number, b is y-intercept and m is the slope. The 
total amount of the PCR product in the total reaction mix was then calculated by multiplying the concentration 
by the total volume of the reaction mix. Thereafter, the copy number was calculated retrospectively using molecu-
lar weights of the mRNAs (LPCAT1 = 33004.2 g/mol and LPCAT2 = 32564 g/mol), the actual mass in the reaction 
mix, cell density and Avogadro’s number (6.02 × 1023).
Multiplex cytokine assay. Cytokines were measured using a Milliplex MAP mouse multiplex kit according 
to the manufacturer’s instructions. Calibration curves from the recombinant cytokine standards were prepared 
by serial dilutions in the same media as the culture supernatant (DMEM medium containing 10% foetal bovine 
serum). High and low reference points for each cytokine were included to determine cytokine recovery. The level 
of detection for each cytokine assayed was 3.2–10000 pg/mL.
Measurement of TNF-a and IL-6 release from human monocytic cells. To determine the differen-
tial effects of reduced LPCAT2 gene expression on cytokine production in response to LPS in human monocytic 
cell line, control and shRNA lentivirus transduced MM6 cells were incubated at a density of 0.5 × 106 /mL in the 
presence or absence or LPS (100 ng/ml) for 4 or 18 hours. Following incubation, supernatants were collected and 
stored at –80 °C. TNF-α and IL-6 in cell culture supernatants were quantified by ELISA in accordance with the 
manufacturer’s instructions.
Lipid raft isolation by successive detergent extraction. The lipid raft, non-lipid raft fractions, the 
cytosolic and nuclear fractions were separated using successive detergent extractions as described previously24 
with minor modification. Briefly, once the experiment was finished, cells were washed twice with ice-cold PBS, 
scraped off and pelleted at 160 × g for 5 minutes. The cells were re-suspended in ice-cold Tris-buffer (50 mM, 
pH = 7.5) containing 150 mM NaCl and protease inhibitor and homogenised using the HGM Cell Cracker 
(HGM, Heidelberg, Germany). The lysate was spun at 500 × g for 5 minutes to pellet the nuclei and the superna-
tant was further centrifuged at 20,000 × g for 20 minutes to separate the cytosolic and the membrane fractions. 
The non-raft fraction was isolated by re-suspending and incubating the membrane fraction in 2-(N-morpholino)-
ethanesulphonic acid (MES)-buffered saline (MBS) (25 mM MES (pH = 6.5) containing 150 mM NaCl, 1% 
Triton X-100 and protease Inhibitor) for an hour on ice. The lipid raft fraction was isolated by treating the 
Triton-insoluble fraction that was recovered after the centrifugation at 20,000 using 60 mM a Tris-buffer contain-
ing β-octylglucoside.





































Table 1. Sequences of primers for real time quantitative PCR.
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Immunoblotting. Cell membrane fractions with equal amounts of protein were separated on NuPAGE® 
pre-cast SDS-PAGE and blotted on to a PVDF membrane using a blot module (Life Technologies, UK). The blots 
were blocked with 0.1% low fat dried skimmed milk powder in PBS-0.1% Tween 20®, probed with primary and 
then HRP-conjugated secondary antibodies using SNAP i.d. TM protein detection system (Millipore, UK). The 
proteins on the membrane were detected using a Luminata Crescendo Western HRP substrate (Millipore, UK) 
and analysed using ImageJ.
flow cytometry. Flow cytometry analyses were performed using a FACSAria III flow cytometer (BD 
Biosciences, USA). The RAW264.7 cells were gated and the cell debris were discounted using the forward and 
side scatters profile and 10,000 events were acquired using BD FACSDivaTM software (BD Biosciences, USA) and 
analysed using WinMDI 2.8 software [Joe Trotter, Pharmingen, CA, USA].
Oxidative burst. Total reactive oxygen species (ROS) production was measured in real time by flow cytom-
etry with a Total ROS detection kit as per the supplier’s instructions. Briefly, 0.5×106 cells were seeded onto T25 
culture flasks in complete DMEM medium. After 24 h incubation, the cells were transfected with either nega-
tive or LPCAT2 siRNA using OPTI-MEM medium. The cells from each flask were scraped off and stimulated 
with 1 µg/mL LPS or 1 µM phorbol 12-myristate 13-acetate (PMA). After 20 minutes incubation, the cell suspen-
sions were spun and the cell pellets were washed with the wash buffer supplied with the kit. The cells were then 
re-suspended in ROS detection solution and incubated for 30 minutes at 37 °C in the dark and analysed by flow 
cytometry. The median fluorescence of the stimulated cells transfected with LPCAT2 siRNA was compared with 
the cells transfected with negative siRNA as described by Namgaladze et al., 200925.
Data analysis. Data are shown as means + SE from at least three independents experiments performed in 
duplicate. GraphPad prism (GraphPad Software, La Jolla, California, USA) was used for statistical analysis. Data 
were compared using ANOVA or student t-test and a p-value of <0.05 was considered statistically significant.
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